Effects of MDMA on extra cellular dopamine and serotonin levels in mice lacking dopamine and/or serotonin transporters

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 91-95

  Hagino, Y ^a   Takamatsu, Y ^a   Yamamoto, H ^a   Iwamura, T ^b   Murphy, D L ^c   Uhl, G R ^d   Sora, I ^e   Ikeda, K ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b MATSUYAMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dopamine transporter; Knockout; MDMA; Microdialysis; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; SEROTONIN BRAIN LEVEL; WILD TYPE;

EID: 79953034278     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795017254     Document Type: Article

References (34)

1. Johnson, M.P.; Conarty, P.F.; Nichols, D.E. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol., 1991, 200, 9-16.
2. Fitzgerald, J.L.; Reid, J.J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur. J. Pharmacol., 1990, 191, 217-220.
3. Johnson, M.P.; Hoffman, A.J.; Nichols, D.E. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol., 1986, 132, 269-276.
4. Schmidt, C.J.; Levin, J.A.; Lovenberg, W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol., 1987, 36, 747-755.
5. Rothman, R.B.; Baumann, M.H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol., 2003, 479, 23-40.
6. Han, D.D.; Gu, H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol., 2006, 6, 6.
7. Gudelsky, G.A.; Yamamoto, B.K.; Nash, J.F. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur. J. Pharmacol., 1994, 264, 325-330.
8. Yamamoto, B.K.; Nash, J.F.; Gudelsky, G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther., 1995, 273, 1063-1070.
9. Koch, S.; Galloway, M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm., 1997, 104, 135-146.
10. Baumann, M.H.; Clark, R.D.; Rothman, R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol. Biochem. Behav., 2008, 90, 208-217.
11. Gudelsky, G.A.; Nash, J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem., 1996, 66, 243-249.
12. Nair, S.G.; Gudelsky, G.A. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res., 2004, 1013, 168-173.
13. Trigo, J.M.; Renoir, T.; Lanfumey, L.; Hamon, M.; Lesch, K.P.; Robledo, P.; Maldonado, R. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry, 2007, 62, 669-679.
14. Nash, J.F.; Brodkin, J. Microdialysis studies on 3,4-methylenedioxymethamphetamine- induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther., 1991, 259, 820-825.
15. Shankaran, M.; Yamamoto, B.K.; Gudelsky, G.A. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J. Neurochem., 1999, 72, 2516-2522.
16. Nash, J.F. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci., 1990, 47, 2401-2408.
17. Schmidt, C.J.; Sullivan, C.K.; Fadayel, G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem., 1994, 62, 1382-1389.
18. Bengel, D.; Murphy, D.L.; Andrews, A.M.; Wichems, C.H.; Feltner, D.; Heils, A.; Mossner, R.; Westphal, H.; Lesch, K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (Ecstasy) in serotonin transporter-deficient mice. Mol. Pharmacol., 1998, 53, 649-655.
19. Peng, W.; Simantov, R. Altered gene expression in frontal cortex and midbrain of 3,4-methylenedioxymethamphetamine (MDMA) treated mice: differential regulation of GABA transporter subtypes. J. Neurosci. Res., 2003, 72, 250-258.
20. Giros, B.; Jaber, M.; Jones, S.R.; Wightman, R.M.; Caron, M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996, 379, 606-612.
21. Sora, I.; Wichems, C.; Takahashi, N.; Li, X.F.; Zeng, Z.; Revay, R.; Lesch, K.P.; Murphy, D.L.; Uhl, G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 7699-7704.
22. Ralph, R.J.; Paulus, M.P.; Fumagalli, F.; Caron, M.G.; Geyer, M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci., 2001, 21, 305-313.
23. Powell, S.B.; Lehmann-Masten, V.D.; Paulus, M.P.; Gainetdinov, R.R.; Caron, M.G.; Geyer, M.A. MDMA ecstasy alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berl), 2004, 173, 310-317.
24. Franklin, K.B.J., Paxinos, G. The mouse brain in stereotaxic coordinates. Academic Press: San Diego, 1997.
25. Shen, H.W.; Hagino, Y.; Kobayashi, H.; Shinohara-Tanaka, K.; Ikeda, K.; Yamamoto, H.; Yamamoto, T.; Lesch, K.P.; Murphy, D.L.; Hall, F.S.; Uhl, G.R.; Sora, I. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology, 2004, 29, 1790-1799.
26. Schmidt, C.J.; Lovenberg, W. In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neurosci. Lett., 1985, 59, 9-14.
27. Faraj, B.A.; Olkowski, Z.L.; Jackson, R.T. Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology, 1994, 48, 320-327.
28. Carboni, E.; Tanda, G.L.; Frau, R.; Di Chiara, G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem., 1990, 55, 1067-1070.
29. Yamamoto, B.K.; Novotney, S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem., 1998, 71, 274-280.
30. Moron, J.A.; Brockington, A.; Wise, R.A.; Rocha, B.A.; Hope, B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci., 2002, 22, 389-395.
31. Zhou, F.C.; Lesch, K.P.; Murphy, D.L. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res., 2002, 942, 109-119.
32. Daws, L.C.; Montanez, S.; Owens, W.A.; Gould, G.G., Frazer, A.; Toney, G.M.; Gerhardt, G.A. Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. J. Neurosci. Methods, 2005, 143, 49-62.
33. Liechti, M.E.; Baumann, C.; Gamma, A.; Vollenweider, F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology, 2000, 22, 513-521.
34. Liechti, M.E.; Saur, M.R.; Gamma, A.; Hell, D.; Vollenweider, F.X. Psychological and physiological effects of MDMA (Ecstasy) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology, 2000, 23, 396-404.